This inventor holds 1 USPTO granted patent and 8 published patent applications and 2 EPO patents. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Simon B Lang: Innovator in Plasma Kallikrein Inhibitors
Introduction
Simon B Lang is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of plasma kallikrein inhibitors. His work focuses on creating compounds that can effectively treat various disease states.
Latest Patents
Lang holds a patent for plasma kallikrein inhibitors, which provides a compound of Formula (I) and pharmaceutical compositions. These compounds are designed to treat or prevent conditions such as hereditary angioedema, uveitis, and diabetic retinopathy. The invention emphasizes the selective inhibition of plasma kallikrein, showcasing its potential in therapeutic applications.
Career Highlights
Simon B Lang is associated with Merck Sharp & Dohme Corp., where he continues to advance his research and development efforts. His innovative approach has led to the creation of a valuable patent that addresses critical health issues.
Collaborations
Lang has collaborated with notable colleagues, including Salman Jabri and Anthony K Ogawa. These partnerships have contributed to the success of his research and the development of effective pharmaceutical solutions.
Conclusion
Simon B Lang is a distinguished inventor whose work in plasma kallikrein inhibitors has the potential to impact the treatment of various diseases significantly. His contributions to the pharmaceutical industry highlight the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile